Acorda Therapeutics, Inc. (ACOR)

NASDAQ: ACOR · IEX Real-Time Price · USD
0.469
+0.008 (1.65%)
Aug 12, 2022 10:40 AM EDT - Market open
1.65%
Market Cap 11.38M
Revenue (ttm) 122.74M
Net Income (ttm) -95.02M
Shares Out 24.28M
EPS (ttm) -8.22
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 19,635
Open 0.461
Previous Close 0.461
Day's Range 0.450 - 0.480
52-Week Range 0.280 - 4.990
Beta 0.47
Analysts Buy
Price Target 10.20 (+2,076.7%)
Earnings Date Aug 4, 2022

About ACOR

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for t... [Read more...]

Industry Biotechnology
IPO Date Feb 10, 2006
CEO Ron Cohen
Employees 118
Stock Exchange NASDAQ
Ticker Symbol ACOR
Full Company Profile

Financial Performance

In 2021, ACOR's revenue was $129.07 million, a decrease of -15.62% compared to the previous year's $152.97 million. Losses were -$103.95 million, 4.38% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ACOR stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 2,076.70% from the latest price.

Price Target
$10.2
(2,076.70% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Acorda Therapeutics Reports Second Quarter 2022 Financial Results

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2022 Financial Results

Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022

Why Acorda Therapeutics Shares Gaining Today?

Acorda Therapeutics Inc (NASDAQ: ACOR) announced that Esteve Pharmaceuticals GmbH launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany.  INBRIJA is indicated in the EU for the i...

Esteve Launches INBRIJA® in Germany

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in G...

Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America

ARDSLEY, N.Y. & PANAMA CITY--(BUSINESS WIRE)--Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America

Acorda Therapeutics Reports First Quarter 2022 Financial Results

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2022 Financial Results

Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022

Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022

Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

John Varian Joins Acorda Therapeutics Board of Directors

ARDSLEY, N.Y.--(BUSINESS WIRE)--John Varian joins Acorda Therapeutics Board of Directors

Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team

Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany

Earnings Outlook For Acorda Therapeutics

Acorda Therapeutics (NASDAQ:ACOR) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement.

Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021

Acorda Therapeutics Announces Corporate Restructuring, Management Changes

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Corporate Restructuring, Management Changes

Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of -9.57% and 6.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Acorda Therapeutics Reports Second Quarter 2021 Financial Results

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2021 Financial Results

Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021

Will Acorda Therapeutics (ACOR) Report Negative Q2 Earnings? What You Should Know

Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Acorda Therapeutics Shares Gains On Spain Distribution Pact For Parkinson's Med

Acorda Therapeutics Inc (NASDAQ: ACOR) has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A. to commercialize Inbrija 33 mg (levodopa inhalation powder, hard capsules) in ...

Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain

Acorda Therapeutics Announces Repayment of Convertible Senior Notes

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Repayment of Convertible Senior Notes

Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of 3.15% and 30.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Acorda Therapeutics Reports First Quarter 2021 Financial Results

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2021 Financial Results